Abstract: Compounds including vitamins and aspirin are disclosed. The compounds are provided in dosage form and preferably include selected amounts of folic acid, vitamin D, calcium, vitamin C, thiamine, and riboflavin with the aspirin. A protective coating is preferably provided between the aspirin and the other vitamin and mineral constituents. The dosages are effective in the treatment and prevention of pre-natal conditions.

Abstract: The present invention is for sanitizing compositions for sanitizing surfaces which may contact food. The composition may be provided in liquid form, and may include a quaternary amine, one or more surfactant, a fragrance, and water. At least 90% by weight of the fragrance comprises fragrance components that meet Class I qualifications of the Cramer classification system. All other components of the composition (e.g., the quaternary amine, the surfactants, water, and any optional components) meet the EPA guidelines under CFR 180.940(a). Since the composition only includes components that meet the EPA guidelines under CFR 180.940(a) (reflecting a presumption of low toxicity), and at least 90% of the fragrance itself (e.g., in the case of mixtures of fragrance components) meets the Cramer Class I qualifications, the composition is safe for application to surfaces that come in contact with food, where there is a heightened probability that traces of the composition will be ingested.

Abstract: The present invention is for sanitizing compositions for sanitizing surfaces which may contact food. The composition may be provided in liquid form, and may include a quaternary amine, one or more surfactant, a fragrance, and water. At least 90% by weight of the fragrance comprises fragrance components that meet Class I qualifications of the Cramer classification system. All other components of the composition (e.g., the quaternary amine, the surfactants, water, and any optional components) meet the EPA guidelines under CFR 180.940(a). Since the composition only includes components that meet the EPA guidelines under CFR 180.940(a) (reflecting a presumption of low toxicity), and at least 90% of the fragrance itself (e.g., in the case of mixtures of fragrance components) meets the Cramer Class I qualifications, the composition is safe for application to surfaces that come in contact with food, where there is a heightened probability that traces of the composition will be ingested.

Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubules at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.

Abstract: A PLG copolymer material, termed a PLG(p) copolymer material, adapted for use in a controlled release formulation for a bioactive material is provided, wherein the formulation exhibits a reduced “initial burst” effect when introduced into the tissue of a patient in need thereof. A method of preparation of the PLG copolymer material is also provided, as are methods of use.

Abstract: Disclosed are methods of enhancing plant growth, comprising treating plant seed or the plant that germinates from the seed with an effective amount of at least one chitooligosaccharide, wherein upon harvesting the plant exhibits at least one of increased plant yield measured in terms of bushels/acre, increased root number, increased root length, increased root mass, increased root volume and increased leaf area, compared to untreated plants or plants harvested from untreated seed.

Abstract: Various embodiments disclosed relate to methods and compositions for antimicrobial treatment. In various embodiments, the present invention provides a method of antimicrobial treatment. The method includes at least one of exposing at least one microbe to a magnetic field, and contacting the at least one microbe with at least one nanoparticle including iron.

Abstract: A biosolvent for cleansing surface that provides bactericidal and bacteriostatic activity such that the bacteriostatic activity continues to inhibit bacterial growth on the surface even after rinsing. The biosolvent comprises C2 to C4 alcohols and lactate esters of C2 to C4 alcohols. The bactericidal and bacteriostatic activity are especially useful for cleaning active biological surfaces and in particular for sanitizing hands.

Abstract: The present invention relates to a method of treating or preventing hair loss or excessive hair shedding in a subject by administering to a subject an oral dose of minoxidil. In particular, the present invention relates to a method of treating telogen effluvium in a subject by administering to a subject an oral dose of minoxidil.

Abstract: The invention relates to a method for altering the release characteristics of a long acting drug delivery device containing at least two drugs in different segments, wherein the segments are arranged to a specific sequence. The invention furthermore relates to a drug delivery device with reduced initial burst containing two different drugs in different segments. The invention further relates to a delivery device manufactured according to the a.m. method and its use in contraception and gynecological therapies.

Abstract: The present disclosure relates to a concentrated rinse-off cleansing composition that includes a high concentration of surfactants and conditioning agent(s). For example, the cleansing compositions may include: (a) surfactants system comprising: (i) one or more anionic surfactants selected from: (i-a) alkyl sulfates; alkyl ether sulfates, salts thereof, or a mixture thereof; and (i-b) optionally, one or more non-sulfate anionic surfactants; (ii) one or more alkyl polyglucosides; and (iii) one or more amphoteric surfactants; (b) one or more conditioning agents; and (c) water. The cleansing compositions are particularly useful for cleansing hair.

Abstract: The present disclosure is directed to a sanitizing composition for dispensing into aquatic systems. The sanitizing composition contains a sanitizing agent containing water molecules that have been bound within the composition by a water binder. In one embodiment, the sanitizing agent is a polybiguanide salt and the water binder is an anhydrous salt. The resulting composition can be a solid that can be packaged in water degradable or water soluble packages for ease of handling and dispensing.

Abstract: The present invention generally relates to nitric oxide releasing pharmaceutical compositions and methods of using the same.

Abstract: The invention relates to compositions and methods that include short chain fatty acids (SCFAs), related therapeutic compounds, and other compounds, including combinations thereof, for the treatment or prevention of diseases or disorders.

Abstract: Compositions including at least one dendritic silicone acrylate copolymer and at least one surface-treated pigment, as well as methods of making such compositions and methods of applying such compositions to keratinous material are provided.

Abstract: Compositions including at least one dendritic silicone acrylate copolymer and at least one silicone elastomer resin, as well as methods of making such compositions and methods of applying such compositions to keratinous material are provided.

Abstract: Compositions including at least one dendritic silicone acrylate copolymer, at least one silicone elastomer resin, and at least one surface-treated pigment, as well as methods of making such compositions and methods of applying such compositions to keratinous material are provided.

Abstract: Provided herein is an ophthalmic composition formulated in deuterated water. Also disclosed herein are methods of treating, ameliorating, or reducing ophthalmic conditions or diseases by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.

Abstract: Provided herein is an ophthalmic composition formulated in deuterated water. Also disclosed herein are methods of treating, ameliorating, or reducing ophthalmic conditions or diseases by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.

Abstract: The present Disclosure is directed to methods for inhibiting or suppressing metastasis of a tumor in a mammalian subject using a cysteamine product, e.g., cysteamine or cystamine or a derivative thereof. Also described herein is a method for treating pancreatic cancer in a mammalian subject by administering a cysteamine product described herein.